TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17072963
Drug: Quinacrine (QC)
Normalized name: quinacrine
DrugBank: Quinacrine (DB01103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinacrine (QC) 2 mg/kg bodyweight TID for five days
Study: 14555565
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg bid using a spacer device
Study: 1328941
Drug: Desferrioxamine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 30 mg/kg body-weight (30-min infusion)
Study: 1328941
Drug: Desferrioxamine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine doses of 5, 10, and 20 mg/kg body-weight
Study: 1328941
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 5-10 mg/kg of desferrioxamine
Study: 3899671
Drug: Labetalol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (50 mg hydrochlorothiazide and labetalol)
Study: 3899671
Drug: Prazosin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (50 mg hydrochlorothiazide, 200 mg atenolol and prazosin)
Study: 24823888
Drug: Self-paced, online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-paced, online educational course on complex nursing care of hospitalized patients on basal-bolus insulin
Study: 22982903
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 500 mg
Study: 22982903
Drug: Sevelamer 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 1600 mg
Study: 20473577
Drug: Medium- and
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium- and long-chain triacylglycerols (MLCT) 25-30 g/day
Study: 20473577
Drug: Long-chain triacylglycerols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain triacylglycerols (LCT) 25-30 g/day
Study: 16786754
Drug: Short-term low
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term low dose glucocorticosteroids (GCS), dosage and duration not specified
Study: 8915561
Drug: Phenelzine 45-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine 45-90 mg/day
Study: 22419420
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi training (18 weeks, 45 minutes twice a week)
Study: 10089949
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms/kg by intravenous infusion
Study: 10089949
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group NG)
Study: 8521310
Drug: propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 3 mg.kg‐1
Study: 8521310
Drug: propofol 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 3.5 mg.kg‐1
Study: 30985703
Drug: Jaungo (JUG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaungo (JUG) ointment applied on irradiated skin for 6 weeks, twice a day
Study: 30985703
Drug: Jaungo (JUG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaungo (JUG) ointment
Study: 21869688
Drug: risperidone 2
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 2 mg/d
Study: 21869688
Drug: sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium valproate 600 mg/d
Study: 21869688
Drug: buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone 30 mg/d
Study: 21869688
Drug: trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: trazodone 100 mg/d
Study: 21869688
Drug: thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: thyroid hormone 80 mg/d
Study: 17585029
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI+) (107 mg/d isoflavones)
Study: 17585029
Drug: Alcohol-washed soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-washed soy protein isolate (SPI-) (<6 mg/d isoflavones)
Study: 17585029
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein isolate (0 mg/d isoflavones)
Study: 14718883
Drug: Anterior open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior open bite extraction treatment
Study: 8922769
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg.kg‐1
Study: 8922769
Drug: Midazolam 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.10 mg.kg‐1
Study: 8922769
Drug: Midazolam 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.20 mg.kg‐1
Study: 1359260
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (laser and PTA)
Study: 24310562
Drug: Acipimox (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (750 mg)
Study: 22131689
Drug: Arkapushpa Taila
Normalized name: Mane 'N Tail Mineral Ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arkapushpa Taila Uttarbasti and Krishna Tila Kwatha administered simultaneously
Study: 22131689
Drug: Krishna Tila
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krishna Tila Kwatha administered orally
Study: 22131689
Drug: Placebo wheat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo wheat powder administered orally
Study: 16046988
Drug: Allopurinol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (administered 4 hours and 1 hour before ERCP)
Study: 12172337
Drug: High-dose fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluoxetine (40-60 mg/day)
Study: 12172337
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus desipramine (25-50 mg/day)
Study: 12172337
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus lithium (300-600 mg/day)
Study: 25495361
Drug: Project UPLIFT
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Project UPLIFT (mindfulness-based cognitive therapy)
Study: 22858191
Drug: AGE (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGE (300 mg/tablet) plus CoQ10 (30 mg/tablet)
Study: 9432335
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) for 2 weeks
Study: 9432335
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Metronidazole (500 mg bid) for 1 week
Study: 9432335
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Clarithromycin (500 mg bid) for 1 week
Study: 7945542
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg daily with ranitidine 150 mg daily
Study: 7945542
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg daily without ranitidine (Placebo)
Study: 28347877
Drug: Clonazepam 0.25mg
Normalized name: CLONAZEPAM 0.25MG ORALLY DISINTEG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 0.25mg (GABAA agonist)
Study: 21476152
Drug: Once-daily tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tenofovir DF plus emtricitabine (Truvada, TVD) with efavirenz (EFZ)
Study: 16517193
Drug: Nortriptyline 75
Normalized name: nortriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 75 mg/day
Study: 8826548
Drug: PTF 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTF 400 mg bid
Study: 8826548
Drug: PTF 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTF 400 mg tid
Study: 8826548
Drug: PTF 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTF 400 mg bid or tid
Study: 1417051
Drug: Antipseudomonal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipseudomonal treatment at intervals of four months until serum IgG titre returned to control range
Study: 1417051
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no antipseudomonal treatment)
Study: 20950304
Drug: Sildenafil for
Normalized name: Sildenafil for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil for the treatment of mild ED
Study: 11096333
Drug: Acamprosate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (6 tablets of 333 mg per day)
Study: 8171300
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions used in treatment trials
Study: 22508435
Drug: Wellness Recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellness Recovery Action Planning (WRAP) intervention, consisting of eight weekly 2.5-hour sessions delivered by peers in recovery from serious mental illness.
Study: 18609709
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (LAC): lansoprazole 30 mg, amoxycillin 1 g, clarithromycin 500 mg, all b.d.
Study: 18609709
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (LMBT): lansoprazole 30 mg b.d., metronidazole 500 mg t.d.s., bismuth subcitrate 240 mg b.d., tetracycline chloride 500 mg q.d.s.
Study: 11346861
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg zoledronic acid
Study: 11346861
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg and 8 mg zoledronic acid
Study: 11346861
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg zoledronic acid (retreatment)
Study: 9212042
Drug: L-T4 treatment
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 treatment (20 microg/kg daily for 2 weeks)
Study: 7963146
Drug: Super premium
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super premium ice cream (approximately 16% butterfat)
Study: 3309757
Drug: Thymostimulin for
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin for 2 weeks after the second cycle of chemotherapy
Study: 3309757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional immunotherapy)
Study: 27686345
Drug: Lower threshold
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower threshold (transfusion at 7 g/dl or less)
Study: 27686345
Drug: Higher threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher threshold (transfusion at 9 g/dl or less)
Study: 10945310
Drug: Oral coadministration
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral coadministration of 100 mg talinolol with 0.5 mg digoxin
Study: 10945310
Drug: Coinfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coinfusion of 30 mg talinolol with oral digoxin
Study: 3224001
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with Lipid Research Clinics Coronary Primary Prevention Trial criteria (≥ 265 mg/dL)
Study: 3224001
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with National Cholesterol Education Program (NCEP) criteria (≥ 200 mg/dL)
Study: 3224001
Drug: Follow-up cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up cholesterol determination for hypercholesterolemia subjects (≥ 265 mg/dL at screening)
Study: 28745999
Drug: Tocilizumab weekly
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab weekly (162 mg)
Study: 28745999
Drug: Tocilizumab every
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab every other week (162 mg)
Study: 28745999
Drug: Tocilizumab weekly
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab weekly or every other week
Study: 28745999
Drug: Tocilizumab weekly
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab weekly
Study: 23773357
Drug: Micafungin (MCFG)
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin (MCFG) administered intravenously at a dose of 3 mg/kg/day
Study: 23773357
Drug: Fluconazole (FLCZ)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLCZ) administered intravenously at a dose of 5 mg/kg/day
Study: 21969509
Drug: Oral talactoferrin
Normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Study: 21969509
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Study: 21969509
Drug: Oral talactoferrin
Normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer)
Study: 21969509
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 mL phosphate-based buffer)
Study: 12193492
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at a 15 microg x kg(‐1) dose
Study: 12193492
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at a 30 microg x kg(‐1) dose
Study: 8515293
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g i.v. single dose)
Study: 3052893
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g i.v. before surgery and after 8 hours)
Study: 30346431
Drug: Galantamine 16
Normalized name: galantamine 16 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 16 mg/day for 6 months followed by memantine 20 mg/day for responders
Study: 30346431
Drug: Galantamine 16
Normalized name: galantamine 16 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 16 mg/day for 6 months
Study: 28615375
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 43 g almonds/d
Study: 24267093
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and placebo solutions
Study: 12908658
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Study: 12908658
Drug: Perphenazine (midpotency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (midpotency first generation antipsychotic)
Study: 12908658
Drug: Open-label clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label clozapine or double-blinded second generation drug (available but not assigned in phase 1)
Study: 12908658
Drug: Double-blinded randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded randomization to ziprasidone or another second generation drug (available but not assigned in phase 1)
Study: 11092778
Drug: One-session psychological
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session psychological treatment
Study: 11092778
Drug: Oral selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selected midazolam
Study: 1629885
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg/day)
Study: 6835890
Drug: 0.45 mg
Normalized name: urea 0.45 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg meptazinol/kg/hr
Study: 6835890
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg pethidine/kg/hr
Study: 25331625
Drug: ACT-246475 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 (1,000 mg)
Study: 25331625
Drug: ACT-281959 (F2)
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-281959 (F2) 70 mg
Study: 25331625
Drug: ACT-246475 (dF)
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 (dF) 50 mg
Study: 25331625
Drug: ACT-281959 (F1)
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-281959 (F1) 70 mg
Study: 23526240
Drug: Diclofenac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac + B vitamins mixture (75 mg sodium diclofenac, 100 mg thiamine, 100 mg pyridoxine, 5 mg cyanocobalamin)
Study: 23526240
Drug: Diclofenac alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac alone (75 mg sodium diclofenac)
Study: 15247556
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg BID + Phenytoin 300 mg QD (days 11-22)
Study: 15247556
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg QD + Lopinavir/ritonavir 400/100 mg BID (days 12-23)
Study: 11243418
Drug: Almotriptan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 50 mg
Study: 8988349
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of intranasal salmon calcitonin (sCT) 200 IE
Study: 8988349
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of intranasal salmon calcitonin (sCT) 200 IE
Study: 8500919
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of loxapine
Study: 8500919
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of loxapine
Study: 29423947
Drug: AXP1275 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXP1275 (50 mg)
Study: 12814414
Drug: Short-term pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term pre-operative cessation of smoking, counselling and nicotine replacement therapy
Study: 12814414
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of daily smoking habits
Study: 10403266
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice a day)
Study: 7587218
Drug: Estrogen and
Normalized name: Conjugated estrogen and norgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen and estrogen/progestin therapy
Study: 30994410
Drug: Telehealth-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth-based health coaching (INT group) with weekly videoconferencing for health coaching and monthly medical monitoring.
Study: 30994410
Drug: Self-guided (CON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided (CON group) without weekly health coaching.
Study: 30082170
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg once daily) combined with oral etoposide (50 mg once daily on days 1-14 of a 21-day cycle)
Study: 30082170
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with oral etoposide
Study: 20838215
Drug: Trazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100 mg/d before bedtime)
Study: 27950535
Drug: Erlotinib (E)
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (E) 150 mg orally QD plus sulindac (S) 150 mg orally BID (Arm A)
Study: 27950535
Drug: Erlotinib (E)
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (E) 150 mg QD (Arm B)
Study: 27950535
Drug: Adjuvant Erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Erlotinib (E) 150 mg QD for 2 years after postoperative chemoradiotherapy
Study: 16368840
Drug: Dexamethasone group
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone group (lidocaine 1.5% with 2 mL of dexamethasone 8 mg)
Study: 16368840
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lidocaine 1.5% with 2 mL of isotonic saline chloride)
Study: 14551182
Drug: Nefazodone titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone titrated to a daily dose of 400 mg
Study: 14551182
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days
Study: 14551182
Drug: Fluvoxamine titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine titrated to a daily dose of 200 mg
Study: 26263075
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (group O4)
Study: 26263075
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg (group O8)
Study: 26263075
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (group R)
Study: 18822983
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Amantadine tablets for 5 days
Study: 15702134
Drug: High-dose finasteride
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose finasteride
Study: 10404019
Drug: MK-677 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 10 mg for 2 weeks
Study: 10404019
Drug: MK-677 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25 mg for 2 weeks
Study: 10404019
Drug: MK-677 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks
Study: 8567514
Drug: CHO+MCT trial
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+MCT trial (15% CHO solution + 29 g MCT suspension)